Trial ID or NCT#

NCT02416492

Status

NOT RECRUITING

Purpose

The primary purpose of the clinical study is to evaluate the clinical efficacy of intracranial administration of SB623 cells on patients with chronic motor deficit from Traumatic Brain Injury. A secondary purpose of the study is 1) to evaluate the effect of intracranial administration of SB623 cells on disability parameters and 2) to evaluate the safety and tolerability of intracranial administration of SB623 cells. Patients with stable, chronic motor deficits secondary to focal traumatic brain injury must be 12 months post TBI.

Official Title

A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

Eligibility Criteria

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Gary K. Steinberg, MD, PhD
Cerebrovascular neurosurgeon, Moyamoya surgeon, Aneurysm neurosurgeon, Neurosurgeon
Bernard and Ronni Lacroute-William Randolph Hearst Professor in Neurosurgery and Neurosciences and Professor, by courtesy, of Neurology

Contact us to find out if this trial is right for you.

CONTACT

Quiping Qin
(650) 736-9551